Covid-19 Epidemic Lockdown Impact on Psychomotor Performance

January 20, 2024 updated by: Amira Hussin Hussin Mohammed, Delta University for Science and Technology

Covid-19 Epidemic Lockdown Impact on Psychomotor Performance in Egyptian Children

PURPOSE:

To detect the Covid-19 Epidemic Lockdown impact on Psychomotor performance in Egyptian Children.

BACKGROUND:

The corona virus disease (COVID-19) affected virtually all countries including Egypt as records showed 156,397 subjects including all age groups, Adolescents and children represent sector in the records, lockdown can contribute to widespread psychological distress and an increased risk of physical inactivity consequences shortly. Psychomotor disorders are expected during and aftermath of the pandemic. Validated Questionnaires are tools to assess the psychomotor condition during and after pandemic lockdown as safe and valid assessment tool.

HYPOTHESES:

Covid-19 Epidemic Lockdown has an impact on Psychomotor performance in Egyptian Children.

RESEARCH QUESTION:

Does Covid-19 Epidemic Lockdown impact on Psychomotor performance in Egyptian Children?

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Participants will be randomly selected from all provinces in Egypt.

Description

Inclusion Criteria:

100 participants will be chosen according to the following criteria : subject in both sexes and their age will ranged between

  1. 6-9 years.
  2. 10-13 years.
  3. 14-18 years All subjects should be clinically and medically stable

Exclusion Criteria:

Subjects with psychological or Motor impairment will be excluded from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
pre lockdown assessment for physical activity
Time Frame: up to 24 weeks
Google form questionnaires include the physical activity questionnaire.
up to 24 weeks
post lockdown assessment for physical activity
Time Frame: up to 24 weeks
Google form questionnaires include the physical activity questionnaire.
up to 24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 29, 2021

Primary Completion (Actual)

June 25, 2022

Study Completion (Actual)

June 30, 2022

Study Registration Dates

First Submitted

February 17, 2021

First Submitted That Met QC Criteria

February 18, 2021

First Posted (Actual)

February 21, 2021

Study Record Updates

Last Update Posted (Actual)

January 23, 2024

Last Update Submitted That Met QC Criteria

January 20, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Time Frame

12 months after publishing

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid19 Epidemic Lockdown Impact

3
Subscribe